



Express Mail Label No.: EV 246876678 US

Attorney Docket No.: 3500.244

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Junker et al.

Application No.: 09/592,032

Group Art Unit: 1653

Filed: June 12, 2000

Examiner: Liu, Samuel

Confirmation No: 5100

For: Growth Hormone Crystals

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application as evidenced by the assignment from the named inventors to Novo Nordisk A/S in application 07/961,932 that was as recorded on February 4, 1993 at Reel 6423, Frame 0094.

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,117,984, issued September 12, 2000, is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,117,984, issued September 12, 2000, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the